SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+77.25%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.36B
AUM Growth
+$1.36B
(+29%)
Cap. Flow
-$52.8M
Cap. Flow
% of AUM
-3.89%
Top 10 Holdings %
Top 10 Hldgs %
67.88%
Holding
77
New
7
Increased
14
Reduced
17
Closed
16
Top Buys
| 1 |
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
|
$40.6M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$30.2M |
| 3 |
Merck
MRK
|
$21.9M |
| 4 |
Biogen
BIIB
|
$18.9M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$18.8M |
Top Sells
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$46.7M |
| 2 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$26.2M |
| 3 |
Bristol-Myers Squibb
BMY
|
$24.3M |
| 4 |
AGN
Allergan plc
AGN
|
$22.6M |
| 5 |
Amgen
AMGN
|
$17.9M |
Sector Composition
| 1 | Healthcare | 96.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $154M | 11.13% | 1,109,874 | – | – |
|
2
NextCure
NXTC
$13.5M
| $151M | 10.85% | 2,671,856 +150,000 | +6% | +$8.45M |
|
|
KRTX
3
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $142M | 10.24% | 1,885,602 +156,250 | +9% | +$11.8M |
|
|
AMRN
4
Amarin Corp
AMRN
$311M
| $112M | 8.05% | 5,208,305 | – | – |
|
5
Natera
NTRA
$23.1B
| $104M | 7.53% | 3,100,560 | – | – |
|
|
PRNB
6
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $77.6M | 5.6% | 1,417,258 | – | – |
|
7
Y-mAbs Therapeutics
YMAB
$388M
| $68.6M | 4.94% | 2,194,278 +90,000 | +4% | +$2.81M |
|
|
GRTX
8
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $40.6M | 2.93% | +3,083,712 | New | +$40.6M |
|
|
9
BioMarin Pharmaceuticals
BMRN
$11.2B
| $37.4M | 2.69% | 441,872 +356,976 | +420% | +$30.2M |
|
10
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $34.8M | 2.51% | 1,933,221 | – | – |
|
11
Vertex Pharmaceuticals
VRTX
$100B
| $30.5M | 2.2% | 139,164 +17,474 | +14% | +$3.83M |
|
12
Merus
MRUS
$4.98B
| $27.6M | 1.99% | 1,961,039 | – | – |
|
13
PTC Therapeutics
PTCT
$3.92B
| $24.8M | 1.79% | 517,092 +229,847 | +80% | +$11M |
|
|
14
Merck
MRK
$210B
| $21.9M | 1.58% | +240,806 | New | +$21.9M |
|
|
15
Biogen
BIIB
$19.4B
| $18.9M | 1.36% | +63,711 | New | +$18.9M |
|
|
16
Regeneron Pharmaceuticals
REGN
$61.5B
| $18.8M | 1.36% | +50,086 | New | +$18.8M |
|
|
OBSV
17
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $18.1M | 1.31% | 4,749,623 | – | – |
|
18
United Therapeutics
UTHR
$13.8B
| $16.6M | 1.2% | 188,645 -5,369 | -3% | -$473K |
|
|
CCXI
19
DELISTED
ChemoCentryx, Inc.
CCXI
| $14.9M | 1.07% | +376,944 | New | +$14.9M |
|
|
MYOK
20
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $14.3M | 1.03% | 195,871 +81,945 | +72% | +$5.97M |
|
|
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $14M | 1.01% | 108,383 +77,583 | +252% | +$10M |
|
|
NCNA
22
NuCana
NCNA
$6.09M
| $13.8M | 1% | 2,266,666 | – | – |
|
23
MacroGenics
MGNX
$112M
| $12.8M | 0.92% | 1,173,882 +592,328 | +102% | +$6.44M |
|
24
Fate Therapeutics
FATE
$120M
| $12.4M | 0.9% | 635,143 +253,543 | +66% | +$4.96M |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $11.3M | 0.82% | 87,818 -18,596 | -17% | -$2.4M |
|